Pyridoxine dependent epilepsy: Is late onset a predictor for favorable outcome?

Eur J Paediatr Neurol. 2018 Jul;22(4):662-666. doi: 10.1016/j.ejpn.2018.03.009. Epub 2018 Mar 30.

Abstract

Aim: In pyridoxine dependent epilepsy (PDE), patients usually present with neonatal seizures. A small subgroup is characterized by late-onset beyond 2 months of age. We aim to analyze the observation of relatively good cognitive outcome in this subgroup of late-onset PDE patients.

Methods: We retrospectively analyzed data from four metabolically and genetically confirmed late-onset patients with PDE due to antiquitin (ALDH7A1) deficiency. Data were analyzed regarding ALDH7A1 mutations, alpha-Aminoadipic semialdehyde (α-AASA) and pipecolic acid (PA) levels, medication during pregnancy, delivery, treatment delay, amount of seizures, pyridoxine dose, adjuvant therapy and findings on brain MRI.

Results: Results showed that three patients had relatively good outcome (IQ 80-97), while one patient did not undergo formal testing and was considered mildly delayed. We were unable to find a clear association between the above-mentioned variables and cognitive outcome, although a less severe genotype may be present in three patients, and maternal medication could be accountable for better outcome in two patients.

Interpretation: We suggest that favorable outcome in late onset PDE might be explained by a combination of factors. A yet unknown protective factor, different genetic variations, functional variation and secondarily variation in treatment regimens and absence of neonatal seizure induced brain damage.

Keywords: Late onset; Pyridoxine dependent epilepsy.

MeSH terms

  • Age of Onset*
  • Aldehyde Dehydrogenase / genetics
  • Epilepsy / complications*
  • Epilepsy / genetics
  • Female
  • Genotype
  • Humans
  • Infant
  • Intellectual Disability / epidemiology
  • Intellectual Disability / genetics*
  • Intelligence / genetics
  • Magnetic Resonance Imaging
  • Male
  • Mutation
  • Pyridoxine / therapeutic use
  • Retrospective Studies

Substances

  • ALDH7A1 protein, human
  • Aldehyde Dehydrogenase
  • Pyridoxine

Supplementary concepts

  • Pyridoxine-dependent epilepsy